BioLineRx (BLRX) Net Margin (2024 - 2025)
BioLineRx (BLRX) recorded quarterly Net Margin of 1601.03% in Q4 2025, down 821.35% quarter-over-quarter from 173.77% in Q3 2025, and down 160149.0% on a YoY basis from N/an in Q4 2024.
BioLineRx (BLRX) Net Margin (2024 - 2025) Analysis & Trends
BioLineRx's Net Margin history runs 2 years deep, the most recent figure standing at 1601.03% for Q4 2025.
- In Q4 2025, Net Margin fell 160149.0% year-over-year to 1601.03%; the TTM figure through Dec 2025 stood at 573.56% (down 54560.0% YoY), while the FY2025 annual figure was 639.24%, down 60669.0% from the prior year.
- Net Margin was 1601.03% for Q4 2025 at BioLineRx, down from 173.77% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 0.46% in Q4 2024 to a low of 1601.03% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | -1,601.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,601.03% |
| Sep 30, 2025 | -173.77% |
| Jun 30, 2025 | -408.88% |
| Mar 31, 2025 | -657.65% |
| Dec 31, 2024 | 0.46% |
| Sep 30, 2024 | -45.07% |
| Jun 30, 2024 | -47.99% |
| Mar 31, 2024 | -48.55% |